Skip to content
10-Q

Quarterly Report

Zevra Therapeutics, Inc. ZVRA

0001437749-25-016523

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 54.68M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $60.09M
Long Term Debt Q1 2025 · Dec 31, 2024 $59.5M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $37.34M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $33.79M
Current Liabilities Q1 2025 · Mar 31, 2025 $26.98M
Current Liabilities Q1 2025 · Dec 31, 2024 $34.07M
Total Liabilities Q1 2025 · Mar 31, 2025 $131.69M
Total Liabilities Q1 2025 · Dec 31, 2024 $138.46M
Current Assets Q1 2025 · Mar 31, 2025 $81.57M
Current Assets Q1 2025 · Dec 31, 2024 $86.03M
Total Assets Q1 2025 · Mar 31, 2025 $172.71M
Total Assets Q1 2025 · Dec 31, 2024 $178.13M
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$16.17M
Stockholders Equity Q1 2025 · Mar 31, 2024 $48.82M
Stockholders Equity Q1 2025 · Dec 31, 2023 $61.86M
Eps Basic Q1 2025 · Mar 31, 2024 −$0.40
Sga Expense Q1 2025 · Mar 31, 2024 $9.93M
Net Income Q1 2025 · Mar 31, 2024 −$16.62M
Operating Income Q1 2025 · Mar 31, 2024 −$20.49M